Passive Leg Raise and Mini-fluid Challenge Effect on Various Cardiac Output Surrogates for Fluid Responsiveness

Launched by CENTRACARE · Apr 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how two different methods—Passive Leg Raise and Mini-fluid Challenge—can help doctors determine which critically ill patients will benefit from receiving extra fluids. When patients are very sick, sometimes they need fluids to help their organs work properly. However, not everyone responds to fluids in the same way, and giving too much can be harmful. The goal of this study is to find better ways to assess which patients truly need fluids, especially in cases like severe respiratory distress.

To participate in this trial, individuals must be between 30 and 90 years old and diagnosed with specific conditions like vasodilatory shock or severe acute respiratory distress syndrome (ARDS). Participants will be those who are receiving mechanical ventilation and may be deeply sedated or paralyzed. However, people with certain heart issues, arrhythmias, or severe vascular diseases will not be eligible. If you or a loved one qualify and decide to participate, you can expect to undergo assessments that help understand your body's response to fluids, which could guide future treatment decisions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 30 - 90 years
• • Diagnosis of Vasodilatory Shock with no other obvious cause of hypotension
• • Diagnosis of ARDS with PF ratio \< 150 , PEEP \> 8
• • Patients who are under paralysis or deeply sedated, on a mechanical ventilator
• Exclusion Criteria:
• • Patients with arrhythmias including atrial fibrillation
• • Patients with chest tube, intra-abdominal hypertension or with its risk factors
• • Patients with structural heart disease including pulmonary hypertension (RVSP \> 45) and heart failure
• • Patients on extracorporeal support such as ECMO, CRRT or MCS.
• • Patients with COPD with a premorbid FEV1 \< 1.5 L
• • Severe atherosclerotic vascular disease